CClinicalTrials.gg
Active, not recruitingNCT05174910ORSYUpdated Jul 25, 2024

Investigation of the Benefit of Using an Autologous Platelet-rich Fibrin Matrix (Obsidian ASG®) for Treatment of Anastomosis During Rectal Surgery

An interventional study of Obsidian ASG in Anastomotic Leak Rectum, sponsored by Vivostat. Active, not recruiting at 13 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-25.

Sponsored by Vivostat · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Oct 2024, 1 year 11 months ago, but the record still lists the study as active, not recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Anastomotic insufficiency remains one of the most significant problems after rectal resection.The complications following anastomotic insufficiency leads to increased morbidity and mortality with subsequent prolongation of hospital stay and higher costs.

This study is an investigation of the benefit of using an autologous platelet-rich fibrin matrix (Obsidian ASG®) for treatment of anastomosis during rectal surgery - a single-blind, randomized, multicenter pilot study with enrollment of 2x125 patients

The main objective of the study is to investigate on an exploratory basis whether the use of Obsidian ASG® during rectal resection reduces the frequency of postoperative anastomotic insufficiency compared to standard anastomotic technique.

The secondary objectives of the study are to investigate on an exploratory basis:

  • The frequency of anastomotic insufficiency (ISREC Criteria) severity
  • Staple line bleeding requiring surgical intervention
  • The duration of postoperative hospitalization are reduced when using Obsidian ASG ® compared with standard anastomotic treatment alone.

are reduced when Obsidian ASG ® is added to the standard of anastomotic treatment compared with standard anastomotic treatment alone.

02

Conditions studied

  • Anastomotic Leak Rectum

Browse trials for

03

In context

Anastomotic Leak

209 studies on the registry are indexed under Anastomotic Leak; 60 are open to participants now.

This study's planned enrollment of 250 is above the median of 121 across 100 interventional studies indexed under Anastomotic Leak.

Browse Anastomotic Leak studies →

Lead sponsor

Vivostat is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

The following inclusion criteria will be considered:

  • Written informed consent
  • Age > 18 years
  • Indication for elective oncological rectal resection in the presence of malignant rectal disease and the lower edge of the tumor, measured from the anal verge with the rigid rectoscope, ≤ 14cm
  • Use of a circular anastomosis using the "double stapling technique"(6) during creation of the anastomosis
  • Expected availability within the maximum 45-day period of study participation
  • The use of "golden standard" stapling technology devices; 3 rows endo linear stapler; 2 rows circular stapling devices should be used in an open and laparoscopic approach

Exclusion criteria

Exclusion Criteria:

The following exclusion criteria will be considered:

  • Pregnancy, or the non-exclusion of pregnancy (for women of childbearing potential). In the case of menopause having occurred more than 2 years ago or postmenopausal sterilization or surgical sterilization, the authorized physician is free to classify the female study participant as non-pregnant, so that the pregnancy test otherwise required at the beginning of study participation (or during subject screening) may be omitted.
  • Risk of pregnancy occurring while taking part in the study in women not meeting at least one of the following criteria: Onset of menopause more than 2 years ago, postmenopausal sterilization, surgical sterilization, a promise to use contraception (with hormones, coil or diaphragm/condom + spermicide), while enrolled in the study) In the case of onset of menopause more than 2 years ago, postmenopausal sterilization or surgical sterilization, the authorized doctor is free to classify the patient in question as infertile. Furthermore, it is at the discretion of the authorized physician to classify the patient in question on the basis of continuous inpatient care in such a way that the occurrence of pregnancy during participation in the study can be ruled out ("continuous determination of the absence of pregnancy"). If one of the above classifications applies, further measures to ensure that a pregnancy does not occur during the patient's participation in the study may not be required.
  • Breastfeeding period
  • Lack of legal capacity
  • Vulnerable persons according to the law
  • Comorbidity with the potential for relevant impairment of anastomosis durability (leukemia, cirrhosis of the liver, Child Pugh C, etc.)
  • Preoperative anemia with Hb \<8g/dL
  • Participating in another study
  • Patients on Aspirin not able to stop using Aspirin for medical reasons minimum 3 days before taking the blood sampling.
  • Patients on Clopidogrel not able to stop using Clopidogrel for medical reasons minimum 7 days before blood sampling.
  • Patients on other platelet aggregation inhibitor therapies
  • Contraindication for Obsidian ASG®
  • Surgical technique of transanal total mesorectal excision (TaTME)
  • Application of a circular powered stapler in the course of anastomosis supply with GSTTM technology or a 3 row circular stapler use while creating the study anastomosis
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
250 participants (estimated)

Study arms

  • Active comparator
    With Obsidian ASG

    Anastomosis treatment using standard procedure and Obsidian ASG

    Device: Obsidian ASG

  • No intervention
    Without Obsidian ASG

    Anastomosis treatment using standard procedure

Interventions

  • DeviceObsidian ASG

    Application of an autologous platelet-rich fibrin matrix

06

What researchers measure

Primary outcomes

  1. Anastomosis insufficiency [yes/no]

    Anastomosis insufficiency after colorectal surgery with primary anastomosis

    Time frame: 45 days

Secondary outcomes

  1. Anastomotic insufficiency [0/A/B/C]*

    \*ISREC, International Study Group of Rectal Cancer - severity grading of anastomotic leakage

    Time frame: 45 days

  2. Staple suture line bleeding requiring surgical intervention [yes, with surgical intervention / yes, without surgical intervention / no]

    Staple suture line bleeding requiring surgical intervention

    Time frame: 45 days

  3. Postoperative hospital length of stay [days]

    Days spent in hospital after undergoing colorectal surgery

    Time frame: 45 days

07

Study locations

13 sites
  • Krankenhaus der Barmherzigen Brûder
    Graz, 8020, Austria
  • Kepler Universitätsklinikum GmbH, Med campus III
    Linz, 4021, Austria
  • Landesklinikum Wienerneustadt
    Wiener Neustadt, 2700, Austria
  • Krankenhaus der Barmherzigen Brüder Wien
    Wien, 4041, Austria
  • RoMed Klinikum Rosenheim
    Rosenheim, Bavaria 83022, Germany
  • Universität Augsburg
    Augsburg, 86152, Germany
  • Diakonissenkrankenhaus Dresden
    Dresden, 01099, Germany
  • Klinikum Fürth
    Fürth, 90766, Germany
  • Klinikum Nürnberg Nord
    Nürnberg, 90419, Germany
  • University Milano
    Milano, 20122, Italy
  • University Hospital Belgrade
    Belgrade, 11000, Serbia
  • Granada Hospital
    Granada, 18016, Spain
  • Consorci Hospital General Universitari de Valencia
    Valencia, 46016, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05174910
Lead sponsor
Vivostat
Collaborators
Raffeiner GmbH, European Commission, AF Schimetta GMbH, Rivolution GmbH
Responsible party
Sponsor
First posted
Jan 3, 2022
Start date
Dec 23, 2021
Primary completion
Oct 31, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Jul 25, 2024

Study contacts

Andreas Shamiyeh, Prim.Doz.Dr.
principal investigator · Kepler Universitätsklinikum Gmbh

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion